KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Change in Inventory (2017 - 2025)

Historic Change in Inventory for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to $4.6 million.

  • Twist Bioscience's Change in Inventory rose 92410.71% to $4.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.4 million, marking a year-over-year increase of 22803.27%. This contributed to the annual value of $4.2 million for FY2025, which is 15295.52% up from last year.
  • According to the latest figures from Q4 2025, Twist Bioscience's Change in Inventory is $4.6 million, which was up 92410.71% from $2.4 million recorded in Q3 2025.
  • Over the past 5 years, Twist Bioscience's Change in Inventory peaked at $10.6 million during Q3 2021, and registered a low of -$4.7 million during Q1 2023.
  • Moreover, its 5-year median value for Change in Inventory was -$523000.0 (2024), whereas its average is $976150.0.
  • Per our database at Business Quant, Twist Bioscience's Change in Inventory skyrocketed by 130857.14% in 2021 and then crashed by 44670.78% in 2025.
  • Over the past 5 years, Twist Bioscience's Change in Inventory (Quarter) stood at $8.4 million in 2021, then plummeted by 37.4% to $5.3 million in 2022, then crashed by 122.74% to -$1.2 million in 2023, then soared by 53.37% to -$560000.0 in 2024, then skyrocketed by 924.11% to $4.6 million in 2025.
  • Its Change in Inventory stands at $4.6 million for Q4 2025, versus $2.4 million for Q3 2025 and $5.1 million for Q2 2025.